Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP270216.RAHy7oEf3QKTRdPu5sxDFHu5nR5oR10SD_tFVr0o5etpM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP270216.RAHy7oEf3QKTRdPu5sxDFHu5nR5oR10SD_tFVr0o5etpM130_assertion type Assertion NP270216.RAHy7oEf3QKTRdPu5sxDFHu5nR5oR10SD_tFVr0o5etpM130_head.
- NP270216.RAHy7oEf3QKTRdPu5sxDFHu5nR5oR10SD_tFVr0o5etpM130_assertion description "[Of the 80 specimens of primary prostate cancer examined by receptor binding assays, 50 ( approximately 63%) showed high-affinity, low-capacity binding sites for bombesin/GRP, and 12 of these 50 receptor-positive specimens also showed a second binding site.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP270216.RAHy7oEf3QKTRdPu5sxDFHu5nR5oR10SD_tFVr0o5etpM130_provenance.
- NP270216.RAHy7oEf3QKTRdPu5sxDFHu5nR5oR10SD_tFVr0o5etpM130_assertion evidence source_evidence_literature NP270216.RAHy7oEf3QKTRdPu5sxDFHu5nR5oR10SD_tFVr0o5etpM130_provenance.
- NP270216.RAHy7oEf3QKTRdPu5sxDFHu5nR5oR10SD_tFVr0o5etpM130_assertion SIO_000772 10679759 NP270216.RAHy7oEf3QKTRdPu5sxDFHu5nR5oR10SD_tFVr0o5etpM130_provenance.
- NP270216.RAHy7oEf3QKTRdPu5sxDFHu5nR5oR10SD_tFVr0o5etpM130_assertion wasDerivedFrom befree-20140225 NP270216.RAHy7oEf3QKTRdPu5sxDFHu5nR5oR10SD_tFVr0o5etpM130_provenance.
- NP270216.RAHy7oEf3QKTRdPu5sxDFHu5nR5oR10SD_tFVr0o5etpM130_assertion wasGeneratedBy ECO_0000203 NP270216.RAHy7oEf3QKTRdPu5sxDFHu5nR5oR10SD_tFVr0o5etpM130_provenance.